Mikolaj Matloka’s Post

Possible new #narcolepsy, #hypersomnia drug coming. Orexin receptor pathways play vital regulatory roles in many physiological processes and studies have shown that orexin receptor pathways are involved in pathological processes of neurological diseases such as narcolepsy, depression, ischemic stroke, drug addiction and Alzheimer’s disease. https://hubs.li/Q02bSc1F0

Our Mission We are committed to bring hope and relief to patients and their families by developing innovative groundbreaking drugs within Alzheimer’s disease, pain and other devastating disorders. AlzeCure® works with several research platforms: NeuroRestore® and Alzstatin® – with a focus on Alzheimer’s disease, where the leading candidate ACD856 is in clinical development phase. Painless – focuses on pain treatment and contains two projects: ACD440 in clinical development phase and TrkA-NAM in research phase. There are several drug candidates in the various platforms: two candidates in NeuroRestore and two candidates in Alzstatin, as well as two projects that remain in the Painless platform. A diversified portfolio of drug candidates paves the way for other indications, such as cognitive disorders associated with Alzheimer’s, traumatic brain injury, sleep apnea and Parkinson’s disease, as well as for severe pain in conditions such as neuropathy and osteoarthritis. The NeuroRestore platform is a new generation of symptomatic drugs for the treatment of illnesses with cognitive disorders, such as Alzheimer’s disease. The target mechanism also has other potential indications, including depression and cognitive disorders in Parkinson’s disease, traumatic brain injury and sleep disorders. The leading drug candidate in the project, ACD856, is in clinical development phase. Innovative small molecule disease-modifying and preventive drugs for Alzheimer’s disease are under development within the Alzstatin platform. They are intended to enable simple administration of the drug and be more cost-effective. The two Alzstatin projects are in the preclinical development phase. The Painless platform includes two projects: TrkA-NAM and ACD440, which both focus on severe pain. Learn about AlzeCure : https://lnkd.in/enfcx4G #alzecure #alzheimers #alzheimerfonden #redeye #avanza #nordnet #edisongroup #seb #swedbank #nordea #aktiespararna #privataaffarer #vatorsecurities #erikpenser #carlsquare #analysguiden #pharma #medicine #medicalsciences #finwire 

Our Mission We are committed to bring hope and relief to patients and their families by developing innovative groundbreaking drugs within Alzheimer’s disease, pain and other devastating disorders. AlzeCure® works with several research platforms: NeuroRestore® and Alzstatin® – with a focus on Alzheimer’s disease, where the leading candidate ACD856 is in clinical development phase. Painless – focuses on pain treatment and contains two projects: ACD440 in clinical development phase and TrkA-NAM in research phase. There are several drug candidates in the various platforms: two candidates in NeuroRestore and two candidates in Alzstatin, as well as two projects that remain in the Painless platform. A diversified portfolio of drug candidates paves the way for other indications, such as cognitive disorders associated with Alzheimer’s, traumatic brain injury, sleep apnea and Parkinson’s disease, as well as for severe pain in conditions such as neuropathy and osteoarthritis. The NeuroRestore platform is a new generation of symptomatic drugs for the treatment of illnesses with cognitive disorders, such as Alzheimer’s disease. The target mechanism also has other potential indications, including depression and cognitive disorders in Parkinson’s disease, traumatic brain injury and sleep disorders. The leading drug candidate in the project, ACD856, is in clinical development phase. Innovative small molecule disease-modifying and preventive drugs for Alzheimer’s disease are under development within the Alzstatin platform. They are intended to enable simple administration of the drug and be more cost-effective. The two Alzstatin projects are in the preclinical development phase. The Painless platform includes two projects: TrkA-NAM and ACD440, which both focus on severe pain. Learn about AlzeCure : https://lnkd.in/enfcx4G #alzecure #alzheimers #alzheimerfonden #redeye #avanza #nordnet #edisongroup #seb #swedbank #nordea #aktiespararna #privataaffarer #vatorsecurities #erikpenser #carlsquare #analysguiden #pharma #medicine #medicalsciences #finwire 

AlzeCure works with several research platforms: NeuroRestore® and Alzstatin® – with a focus on Alzheimer’s disease, where the leading candidate ACD856 is in clinical development phase. Painless – focuses on pain treatment and contains two projects: ACD440 in clinical development phase and TrkA-NAM in research phase. There are several drug candidates in the various platforms: two candidates in NeuroRestore and two candidates in Alzstatin, as well as two projects that remain in the Painless platform. A diversified portfolio of drug candidates paves the way for other indications, such as cognitive disorders associated with Alzheimer’s, traumatic brain injury, sleep apnea and Parkinson’s disease, as well as for severe pain in conditions such as neuropathy and osteoarthritis. https://lnkd.in/gsqZZucx #alzecure #alzheimer #Painless #ACD856 #ACD440 #Alzstatin #TrkANAM

New research from the IoPPN has demonstrated the safety and tolerability of a new drug treatment designed as a therapeutic intervention for spinal cord injury (SCI). The research found that the KCL-286 drug – which works by activating retinoic acid receptor beta (RARb) in the spine to promote recovery - was well tolerated by participants in a Phase 1 clinical trial, with no severe side effects. This study represents an important first step in demonstrating the potential for therapeutic interventions for spinal cord injuries. Click the link below to read the story 🔗 #KingsIoPPN #IoPPNNews #SpinalCordInjury #SCI

You might know of MDMA or ecstasy as an illegal “party” drug, but did you know it’s gaining significant traction in the therapy world… MDMA is being trialled on patients suffering from Post-Traumatic Stress Disorder, and it has shown some excellent results. It will also be the first time in 25 years that the FDA will review a new treatment for PTSD. The company responsible for this is called Lykos Therapeutics. They have been leading the charge in the psychedelic space and have become the first psychedelic maker to apply for FDA approval and have an application accepted for review. I think this is excellent news, and I hope we see similar progress around the world. The most effective drug should always be the first choice regardless of the stigma attached to it!

New Client feature in Clinical Leader! Delving into the uncharted waters of psychedelic therapy, Enveric Biosciences, Inc. steered by CEO Joseph Tucker, Ph.D., is on an unwavering mission to attain regulatory approval for their hallucinogenic and non-hallucinogenic therapies. This pursuit involves understanding and maneuvering the intricate regulatory environments of both the U.S. and Australia, providing a captivating insight into the exhilaration and challenges associated with spearheading such revolutionary treatments. Enveric's therapeutic arsenal includes small molecule therapies designed to mitigate the symptoms of anxiety, depression, and addiction disorders. These therapies comprise a mix of hallucinogenic and non-hallucinogenic compounds. EB-373, the firm's frontrunner, is a next-generation synthetic prodrug of psilocin's active metabolite and is poised to commence Phase 1 clinical trial in the early part of 2024. Check out the full piece here:

The FDA's recently drafted guidance intends to help #psychedelic drug researchers develop psychedelic drugs that are safe and effective for treating medical conditions including depression, anxiety, PTSD, and substance abuse disorders. This milestone impacts Silo Pharma’s continuous efforts to merge traditional therapeutics with #psychedelicresearch by providing a clear path for our R&D team that is actively working to develop #psilocybin and #ketamine-based therapies for patients with underserved conditions. More on the FDA’s recent news here: https://lnkd.in/gQqbqgP2 Learn about our pipeline: https://lnkd.in/gvQqv7w5

Applied Therapeutics announced FDA acceptance and priority review of new drug application for Govorestat for the treatment of classic galactosemia. Govorestat is a central nervous system (CNS) penetrant Aldose Reductase Inhibitor (ARI) in development for the treatment of several rare neurological diseases, including Galactosemia, SORD Deficiency, and PMM2-CDG. Chemenu team is always committed to developing more compounds for drug discovery. Here come the related building blocks we can provide: https://lnkd.in/g7GT8Gkf 👇   #Chemenu #AppliedTherapeutics #FDA #Govorestat #galactosemia #CNS #ARI #neurologicaldiseases #SORDDeficiency #PMM2-CDG #drugdiscovery #buildingblocks